Cellect Biotechnology Ltd. announced that Mr. Eyal Leibovitz formally steps-in to assume his role as the company’s Chief Financial Officer, effective January 1, 2017. Mr. Leibovitz has over 27 years of experience in senior management positions in finance, investor relations, M&A, and business development at global pharmaceutical and biotechnology companies. He has served as Chief Financial Officer of several publicly-traded biotechnology companies, including Kamada Ltd. and Evogene Ltd. Among his many achievements, Mr. Leibovitz led Kamada through multiple successful financings (including PIPE round, public rights offering, venture lending and public convertible debt), and oversaw the sale of N-trig Ltd. to Microsoft. In his roles at each of these companies, Mr. Leibovitz held full responsibility for financial reporting, budget control, financial planning, strategic negotiations, investor relations/public relations, legal proceedings, operations and Human Resources.